Colorectal cancer prognostics

• US 20040191782A1
• Filed: 03/31/2003
• Published: 09/30/2004
• Est. Priority Date: 03/31/2003
• Status: Abandoned Application

• Current Assignee: Lcc Veridex
• Original Assignee: Lcc Veridex
• Inventors: Wang, Yixin
• Application Number:
  US10/403,449
• Publication Number:
  US 20040191782A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: G01N 33/57419 of colon

Abstract

A method of providing a prognosis of colorectal cancer is conducted by analyzing the expression of a group of genes. Gene expresson profiles in a variety of medium such as microarrays are included as are kits that contain them.

Claims

1. A method of assessing colorectal cancer status comprising identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from the group consisting of Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

2. The method of claim 1 wherein the combination of genes is Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

3. The method of claim 1 wherein the combination of genes is Seq. ID. No. 2, Seq. ID. No.3, and Seq. ID No. 4.

4. The method of claim 1 wherein there is at least a 2 fold difference in the expression of the modulated genes.

5. The method of claim 1 wherein the p-value indicating differential modulation is less than 0.05.

6. The method of claim 1 further comprising a colorectal diagnostic that is not genetically based.

7. A prognostic portfolio comprising isolated nucleic acid sequences, their complements, or portions thereof of a combination of genes selected from the group consisting of Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

8. The portfolio of claim 7 wherein the combination of genes is Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

9. The portfolio of claim 7 wherein the combination of genes is Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

10. The portfolio of claim 7 in a matrix suitable for identifying the differential expression of the genes contained therein.

11. The portfolio of claim 10 wherein said matrix is employed in a microarray.

12. The portfolio of claim 11 wherein said microarray is a cDNA microarray.

13. The portfolio of claim 11 wherein said microarray is an oligonucleotide microarray.

14. A kit for determining the prognosis of a colorectal cancer patient comprising materials for detecting isolated nucleic acid sequences, their compliments, or portions thereof of a combination of genes selected from the group consisting of Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

15. The kit of claim 14 wherein the genes are Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

16. The kit of claim 14 wherein the genes are Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

17. The kit of claim 14 comprising reagents for conducting a microarray analysis.

18. The kit of claim 14 further comprising a medium through which said nucleic acid sequences, their compliments, or portions thereof are assayed.

19. A method of assessing response to treatment for colorectal cancer comprising identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from the group consisting of Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

20. Articles for assessing colorectal cancer status comprising materials for identifying nucleic acid sequences, their complements, or portions thereof of a combination of genes selected from the group consisting of Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.

21. Articles for assessing colorectal cancer status comprising representations of isolated nucleic acid sequences, their complements, or portions thereof of a combination of genes selected from the group consisting of Seq. ID. No. 1, Seq. ID. No. 2, Seq. ID. No. 3, and Seq. ID. No. 4.